Venture Kick

Unomr develops novel nano-​micro technology based sensing approaches for diagnostics and drug discovery.

Scanvio offers AI-augmented ultrasound software for faster endometriosis diagnosis, providing expert sonography skills to gynecologists, improving health and surgical education.

TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Sensawear is a medical technology company that specializes in the production of wearable, textile-integrated sensors. These sensors monitor tissue oxygenation and skin pressure in real-time, alerting users to potential pressure injuries before they occur. By providing early warnings of low-oxygenation conditions caused by high-pressure points, Sensawear's products enable users to take preventative action, such as moving or being moved, thus minimizing the risk of painful and dangerous pressure ulcers.

SightIn Health is a Swiss company founded in 2021 that specializes in artificial intelligence-powered software for portable ultrasound devices. The firm has developed an imaging platform that enhances the functionality of ultrasound machines by providing automated quality assessments, probe guidance, and image analysis. This technology aims to reduce the skill barrier traditionally associated with ultrasound equipment, making it easier for healthcare providers to capture and interpret medical images. By improving the accuracy of medical diagnostics and prognostics, SightIn Health supports healthcare companies in delivering better patient care.

Maven Health is a health tech company that provides an end-to-end metabolic health solution designed for healthcare providers. It specializes in assessing individuals' metabolic health using saliva as the bio-fluid for metabolite measurements. These measurements are analyzed with advanced Nuclear Magnetic Resonance (NMR) spectrometers employing custom analytical methods. The system is designed to be minimally invasive and cost-effective, assisting healthcare professionals in identifying at-risk individuals who may not be recognized through traditional healthcare practices. The results are delivered through an intuitive data platform, facilitating better decision-making and patient care.

YLAH specializes in creating web and mobile applications tailored for psychotherapists and their patients. The company focuses on developing technology that delivers individualized therapies, clinical assessments, and health monitoring. This digital tool enables therapists to enhance and scale their services effectively, improving the overall therapeutic experience for patients.

Avelo is a manufacturer of diagnostic equipment focused on infectious diseases. The company has developed a non-invasive breath aerosol testing system that allows for rapid detection of multiple lower respiratory tract infections. This innovative product enables primary care providers to conduct quick sample-to-answer tests, providing results within minutes through a streamlined three-step process. By facilitating early diagnosis, Avelo's technology aims to improve patient outcomes through timely antibiotic or antiviral treatment and efficient patient referrals. The company's mission centers on enhancing the speed and accuracy of infectious disease diagnoses to ultimately save lives.

NexMR is a Swiss company focused on enhancing drug discovery processes through its nuclear magnetic resonance (NMR) platform. The company offers comprehensive solutions designed to optimize throughput and resource utilization within drug discovery pipelines. By utilizing a proprietary NMR technique, NexMR enables rapid screening of libraries containing thousands of molecules, significantly accelerating the drug design process. The integration of machine learning enhances data analysis, allowing for exploration of previously uncharted targets. Additionally, NexMR's technology aids in quality control and research, facilitating the assessment of chemical samples' content, purity, and molecular structure. This capability supports healthcare professionals in evaluating the potential of new compounds and improving experimental turnaround times.

NexMR is a Swiss company focused on enhancing drug discovery processes through its nuclear magnetic resonance (NMR) platform. The company offers comprehensive solutions designed to optimize throughput and resource utilization within drug discovery pipelines. By utilizing a proprietary NMR technique, NexMR enables rapid screening of libraries containing thousands of molecules, significantly accelerating the drug design process. The integration of machine learning enhances data analysis, allowing for exploration of previously uncharted targets. Additionally, NexMR's technology aids in quality control and research, facilitating the assessment of chemical samples' content, purity, and molecular structure. This capability supports healthcare professionals in evaluating the potential of new compounds and improving experimental turnaround times.

Sensemodi develops an AI-powered smart wearable device that assesses joint health, particularly focusing on the knee and other joints. By utilizing a combination of thermal, acoustic, and kinematic data, the device provides a quick evaluation of joint conditions. This innovative technology aims to prevent disabilities and reduce the socioeconomic burden associated with musculoskeletal disorders. The wearable allows users to conveniently monitor their joint health, facilitating access to improved healthcare treatments and promoting proactive management of joint-related issues.

Oncobit is focused on enhancing personalized cancer care through the development of precise and highly sensitive diagnostic and monitoring tests. The company combines technical expertise with proprietary software and engages in close clinical collaborations, initially concentrating on melanoma while maintaining the potential to expand its solutions to other cancer types. Oncobit's innovative approach aims to improve patient outcomes by providing comprehensive and sensitive tests that enable clinics to offer tailored therapies and diagnostics, ensuring that cancer monitoring keeps pace with advancements in treatment methodologies.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers designed to diagnose neurological disorders. By leveraging advanced technology, Nemosia creates tracers that facilitate the early identification of neurodegenerative diseases. Their products utilize PET imaging to visualize N-methyl-D-aspartate (NMDA) receptors in the brain, allowing for timely intervention and management of neurological conditions. This innovative approach aims to enhance diagnostic capabilities and improve patient outcomes in the field of neurology.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.

4iLabs is developing a diagnostic toolbox to support clinicians in the therapy decision-making process for patients with progressed cancer beyond the standard of care.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.

Emovo Care SA, founded in 2020 and located in Lausanne, Switzerland, develops a robotic hand orthosis aimed at individuals with motor impairments resulting from stroke. The company is ISO 13485 certified and focuses on creating accessible robotic devices that facilitate movement at home for hemiparetic stroke patients. Their flagship product is an active orthosis designed to enable users to move their hands independently, enhancing rehabilitation efforts. The device is accompanied by a mobile application that tracks usage and motivates users, thereby providing value to patients, clinicians, and health insurers. The core technology behind the orthosis emerged from research conducted during a PhD program at EPFL, which garnered significant international media attention for its innovative approach to brain-computer interfaces. The product is expected to receive CE marking by 2022.

Nutrix is a Swiss health-tech company founded in 2019 and based in Basel. It specializes in developing a nanosensor that is placed on the tooth to measure glucose levels in saliva, providing a non-invasive method for users to monitor their health. This technology is integrated with an external application that tracks food intake and offers dietary advice, aiming to aid in the prevention of diabetes. Nutrix combines artificial intelligence with wearables to create cost-effective healthcare solutions. In 2025, the company plans to introduce CortiSense, a non-invasive cortisol monitoring sensor that has already received a CES Innovation Award, further expanding its portfolio of health monitoring technologies. Through its innovative approach, Nutrix enables users to manage their health conditions effectively without the need for frequent medical consultations.

epyMetrics AG is a Swiss health analytics company that specializes in developing diagnostic wearable solutions aimed at monitoring the body's heat balance. Incorporated in 2019 and based in Zurich, the company offers a comprehensive platform that enables users to continuously and non-invasively track their thermoregulation. Its technology detects early signs of heat stress, facilitating the prevention of heat-related accidents. The wearable device captures vital signs, including sweat rate and total sweat loss, providing crucial data that allows industries to identify the risk of heat exhaustion. By offering personalized safety benchmarks, epyMetrics aims to enhance safety protocols and reduce costs associated with heat-related incidents.

MimiX Biotherapeutics Sàrl, established in 2016 and based in La Tène, Switzerland, specializes in the development of biofabrication technology for therapeutic and diagnostic applications. The company focuses on creating an ultra-fast biomanufacturing process that enables the production of patient-specific biological tissue equivalents. This innovative approach supports regenerative medicine and personalized healthcare, allowing for tailored treatments that meet individual patient needs. By advancing tissue engineering techniques, MimiX Biotherapeutics aims to enhance the precision and effectiveness of medical interventions.

Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.

OptiChroniX is a Swiss digital health solution company focused on enhancing brain health through early intervention. The company develops digital health interventions that combine biomedical, behavioral, computing, and engineering research, which are accessible via smartphones. These interventions allow patients to personalize and monitor their brain health by integrating data from various wearables. By offering tailored coaching, OptiChroniX aims to improve health literacy and medication adherence, addressing modifiable risk factors linked to cognitive decline, particularly in patients with Alzheimer’s disease and related co-morbidities. The company's mission is to optimize lifestyle choices and make healthcare more effective, ultimately enhancing clinical outcomes and quality of life.

Testmate Health is a medtech startup and an award-winning spin-off of the University of Geneva, focused on developing innovative healthcare solutions. The company has created a smartphone-compatible test kit that can diagnose diseases with identifiable DNA or RNA sequences, providing results directly at home in just minutes. Its first product is a rapid urine self-test for the four most common sexually transmitted diseases, addressing the urgent need for timely diagnosis, as one million new STDs are diagnosed daily. Traditional testing often requires lab work and can take up to seven days for results. Testmate Health's all-in-one kit is designed for ease of use, allowing users to obtain immediate results that can be scanned by a smartphone for quick access to treatment if necessary. The company is also working on additional test kits for other diseases, aiming to empower individuals to manage their health conveniently from home.

Swiss Medical Union SA, founded in 2019 and based in Yverdon-les-Bains, Switzerland, specializes in healthcare technology focused on testing the interaction, efficiency, and safety of new medical products. The company manufactures Micro-Bioreactor equipment that allows for ex vivo testing with human organ and tissue models, enabling the selection of appropriate therapies tailored to individual patient needs. Additionally, Swiss Medical Union develops software that simulates organ activity, analyzes interactions between medical products and specific organs, and monitors real-time effects of treatments within the circulatory system. The company also provides clinical testing services aimed at supporting healthcare professionals in making informed clinical decisions, particularly in cancer treatment. Its offerings are designed to enhance therapeutic outcomes while minimizing the risks associated with unnecessary treatments.

C-MedTec is focused on developing a diagnostic helmet that enhances the detection and monitoring of brain concussions, addressing a critical gap in current medical practices. Traditional methods rely on subjective assessments performed by trained professionals, leaving a void in timely diagnosis and proper care. The innovative helmet measures brain metabolism and identifies abnormal neurological behavior following head trauma, facilitating early detection and diagnosis. This advancement aims to provide medical centers and sports organizations with the necessary tools to promote safer sporting practices and reduce the risk of long-term effects associated with repeated brain injuries, such as Alzheimer's disease and chronic traumatic encephalopathy (CTE).

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of EmbryoSpin, an innovative device designed for biochemical research. This device performs microscopic nuclear magnetic resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold, allowing for chemical analysis at the scale of a single human embryo. EmbryoSpin is engineered for robustness and user-friendliness, making it suitable for non-invasive embryo viability screening in in-vitro fertilization and various biochemical studies. The company's advancements aim to enhance medical research capabilities, particularly in the context of reproductive health.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

B-rayZ is a spin-off from the University Hospital Zurich, focused on enhancing radiology through advanced technology. The team comprises experienced radiologists, data scientists, and physicians with over 15 years of expertise in medical imaging. B-rayZ develops artificial intelligence-based software that aids radiologists in mammography by offering real-time assessments of image quality and breast density. This innovative software enables accurate and standardized evaluations of medical imaging data, thereby improving breast cancer detectability. By providing intelligent tools, B-rayZ supports radiologists in enhancing their diagnostic capabilities while also contributing to reduced healthcare costs.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

MOMM Diagnostics is a Swiss company founded in 2018 and headquartered in Basel. It specializes in the development of an in-vitro diagnostic test aimed at the early diagnosis of preeclampsia, a serious condition that can affect pregnant women. The company's innovative diagnostic device is designed for use at the point of care, allowing for quicker diagnosis and intervention, thereby improving patient outcomes. By focusing on women's health, MOMM Diagnostics aims to provide essential support to healthcare providers and enhance the care of pregnant women experiencing potential complications.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of EmbryoSpin, an innovative device designed for biochemical research. This device performs microscopic nuclear magnetic resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold, allowing for chemical analysis at the scale of a single human embryo. EmbryoSpin is engineered for robustness and user-friendliness, making it suitable for non-invasive embryo viability screening in in-vitro fertilization and various biochemical studies. The company's advancements aim to enhance medical research capabilities, particularly in the context of reproductive health.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. The platform utilizes machine learning, artificial intelligence, and search algorithms to identify available caregivers in specific regions, allowing patients to easily find and book appointments with doctors and physicians who offer private care services in their homes. This service aims to streamline the process of accessing healthcare while ensuring patients receive the medical attention they need in the comfort of their own environment.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

IDUN Technologies AG is a Swiss neurotechnology startup founded in 2017, specializing in the design and manufacture of advanced biosensors for wearable devices. The company’s flagship product, DRYODES, features dry conductive electrodes that facilitate bio-potential monitoring, including electrocardiography (ECG), electroencephalography (EEG), and electromyography (EMG). IDUN Technologies aims to integrate neuroscience into everyday products, allowing connected devices to understand and respond to users' emotional needs through real-time neuro-markers. By developing innovative biosensor technology and a comprehensive neurofeedback value chain—from electrode manufacturing to product integration—IDUN enables industries to harness brain signal monitoring for enhanced user experiences. The company's Guardian Neuro-Intelligence Platform exemplifies this approach, utilizing in-ear EEGs to provide actionable insights that improve product design and interaction. Through this integration of emotion intelligence and connected devices, IDUN Technologies aspires to foster a more connected and empathetic world.

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. The platform utilizes machine learning, artificial intelligence, and search algorithms to identify available caregivers in specific regions, allowing patients to easily find and book appointments with doctors and physicians who offer private care services in their homes. This service aims to streamline the process of accessing healthcare while ensuring patients receive the medical attention they need in the comfort of their own environment.

REM Analytics SA specializes in developing analytical techniques for the microbiome therapy sector. Founded in 2020 and based in Lausanne, Switzerland, the company offers services that accurately profile the microtype of individuals. Utilizing innovative lineage tracking technology, REM Analytics measures the colonization of specific probiotic strains within the human microbiome, assessing their effectiveness and the effects of dietary and lifestyle changes. The company's goal is to facilitate the creation of evidence-based, personalized microbiome treatments, thereby enhancing the overall impact of products in the microbiome industry.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

IDUN Technologies AG is a Swiss neurotechnology startup founded in 2017, specializing in the design and manufacture of advanced biosensors for wearable devices. The company’s flagship product, DRYODES, features dry conductive electrodes that facilitate bio-potential monitoring, including electrocardiography (ECG), electroencephalography (EEG), and electromyography (EMG). IDUN Technologies aims to integrate neuroscience into everyday products, allowing connected devices to understand and respond to users' emotional needs through real-time neuro-markers. By developing innovative biosensor technology and a comprehensive neurofeedback value chain—from electrode manufacturing to product integration—IDUN enables industries to harness brain signal monitoring for enhanced user experiences. The company's Guardian Neuro-Intelligence Platform exemplifies this approach, utilizing in-ear EEGs to provide actionable insights that improve product design and interaction. Through this integration of emotion intelligence and connected devices, IDUN Technologies aspires to foster a more connected and empathetic world.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

Certus Molecular Diagnostics AG, founded in 2007 and based in Bern, Switzerland, specializes in the development and delivery of molecular rapid tests. These tests are designed for the on-site detection of mycoplasma contamination in cell cultures, as well as for identifying specific genes in various microorganisms. Certus aims to provide reliable diagnostic solutions that enhance the efficiency and accuracy of testing in both local and international markets.

IDUN Technologies AG is a Swiss neurotechnology startup founded in 2017, specializing in the design and manufacture of advanced biosensors for wearable devices. The company’s flagship product, DRYODES, features dry conductive electrodes that facilitate bio-potential monitoring, including electrocardiography (ECG), electroencephalography (EEG), and electromyography (EMG). IDUN Technologies aims to integrate neuroscience into everyday products, allowing connected devices to understand and respond to users' emotional needs through real-time neuro-markers. By developing innovative biosensor technology and a comprehensive neurofeedback value chain—from electrode manufacturing to product integration—IDUN enables industries to harness brain signal monitoring for enhanced user experiences. The company's Guardian Neuro-Intelligence Platform exemplifies this approach, utilizing in-ear EEGs to provide actionable insights that improve product design and interaction. Through this integration of emotion intelligence and connected devices, IDUN Technologies aspires to foster a more connected and empathetic world.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

MesenFlow Technologies specializes in bio-imaging technology aimed at enhancing drug and cosmetic development. The company has created a platform that accelerates the drug development process by addressing challenges related to species cross-reactivity, animal testing, and understanding human diseases. Utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and translational relevance. The technology has also been adapted for the cosmetics and nutrition sectors, allowing for the assessment of the physiological impact of cosmetic or nutraceutical candidates during the early development phase. This approach supports environments where animal-free testing is essential and emphasizes the importance of understanding human biology in product development.

Komed Health offers a secure messaging platform designed to enhance communication among medical teams and between healthcare professionals and patients. This application streamlines and organizes real-time communication, replacing traditional methods like phones, pagers, and emails. It integrates seamlessly with existing clinical systems, facilitating integrated care pathways and enabling better decision-making by allowing physicians and nurses to access and share vital medical information at the point of care. The company collaborates closely with healthcare providers to develop features that cater specifically to the needs of modern healthcare professionals and workflows, aiming to improve care delivery through efficient and intelligent communication.

Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.

Komed Health offers a secure messaging platform designed to enhance communication among medical teams and between healthcare professionals and patients. This application streamlines and organizes real-time communication, replacing traditional methods like phones, pagers, and emails. It integrates seamlessly with existing clinical systems, facilitating integrated care pathways and enabling better decision-making by allowing physicians and nurses to access and share vital medical information at the point of care. The company collaborates closely with healthcare providers to develop features that cater specifically to the needs of modern healthcare professionals and workflows, aiming to improve care delivery through efficient and intelligent communication.

Immunas develops a point-of-care diagnostic device that within minutes will be able to determine if the source of infection is bacterial or viral. This will lead to informed antibiotic treatment decisions and reduce the number of avoidable deaths in societies due to antimicrobial resistance. Immunas is a med-tech start-up aiming to develop a rapid test allowing doctors to accurately distinguish the sources of infection. The test reduces antibiotic overuse and helps minimize antibiotic resistance. Patients receive optimal treatment faster with the test. Unlike traditional procedures that take hours to days to complete, Immunas' cutting edge chip-based technology, within minutes, will be able to accurately determine whether the cause of infection is bacterial or viral. Together with cost-effectiveness, ease-of-use, minimal invasiveness for the patient and immense potential impact on pressing public health concerns, we genuinely hope to enable smart and responsible use of antibiotics for the benefits of patients and for societies at large.

Kinastic AG, based in Winterthur, Switzerland, specializes in digital solutions for the fitness and wellness market. Founded in 2016, the company offers a multi-industry platform that connects organizations with their communities to promote health and fitness among employees and clients. Kinastic provides two main products: Kinastic Club, which facilitates the creation and sharing of personalized workout programs, and Kinastic Coach, an AI-driven virtual personal trainer that develops individualized training plans. This digital health management tool aims to support enterprises in enhancing employee well-being by offering tailored workout planning, progress tracking, and motivational reminders, thereby fostering a holistic approach to health and wellness within organizations.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing innovative treatments for gastrointestinal diseases. Founded in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create microbiome therapies aimed at conditions such as Clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome's technology platform enables efficient development and production of defined, function-based therapies, facilitating a swift transition from identifying therapeutic mechanisms to clinical-ready products. The company aims to establish microbiota therapy as the new standard for treating intestinal diseases, providing alternatives to traditional fecal transplants for patients suffering from intestinal infections.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing innovative treatments for gastrointestinal diseases. Founded in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create microbiome therapies aimed at conditions such as Clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome's technology platform enables efficient development and production of defined, function-based therapies, facilitating a swift transition from identifying therapeutic mechanisms to clinical-ready products. The company aims to establish microbiota therapy as the new standard for treating intestinal diseases, providing alternatives to traditional fecal transplants for patients suffering from intestinal infections.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing innovative treatments for gastrointestinal diseases. Founded in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create microbiome therapies aimed at conditions such as Clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome's technology platform enables efficient development and production of defined, function-based therapies, facilitating a swift transition from identifying therapeutic mechanisms to clinical-ready products. The company aims to establish microbiota therapy as the new standard for treating intestinal diseases, providing alternatives to traditional fecal transplants for patients suffering from intestinal infections.

SimplicityBio is a Swiss company founded in 2013 that focuses on biomarker discovery within the molecular diagnostics market. Utilizing an artificial intelligence-based platform, the company analyzes biological, clinical, and digital data streams to generate insights that facilitate the development process from target identification through pre-clinical and clinical phases. Its technology employs algorithms to explore biomarker signatures and identifies models based on user-defined criteria. SimplicityBio offers a range of services, including biomarker discovery and ranking, signature creation, and enhancement of existing signatures. The company also develops scientific innovations and intellectual property for its clients, positioning itself as a leader in the biomarker discovery sector. As of 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

SimplicityBio is a Swiss company founded in 2013 that focuses on biomarker discovery within the molecular diagnostics market. Utilizing an artificial intelligence-based platform, the company analyzes biological, clinical, and digital data streams to generate insights that facilitate the development process from target identification through pre-clinical and clinical phases. Its technology employs algorithms to explore biomarker signatures and identifies models based on user-defined criteria. SimplicityBio offers a range of services, including biomarker discovery and ranking, signature creation, and enhancement of existing signatures. The company also develops scientific innovations and intellectual property for its clients, positioning itself as a leader in the biomarker discovery sector. As of 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Point-of-care testing for smoke poisoning.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Calciscon AG is a Swiss diagnostic company based in Nidau, established in 2013. It specializes in developing and selling calcification blood test kits aimed at patients with chronic kidney diseases. The company's primary focus is on improving cardiovascular risk management for kidney patients through its calcification propensity diagnostics. Calciscon's testing services measure various indicators such as crystal formation time, serum magnesium, and fetuin-A levels, helping to identify individuals at elevated risk for pathological calcification. The company serves a diverse clientele, including researchers, clinical laboratories, and other companies, with the goal of becoming a leader in assessing, preventing, and treating biomineralization-related medical issues.

Medopticon / Panopticon is an innovative tumor analysis and classification platform.

Point-of-care testing for smoke poisoning.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular, cartridge-based system maintains sample quality, integrates with standard lab processes, and aims to make blood collection more accessible and convenient for patients and healthcare professionals.

Calciscon AG is a Swiss diagnostic company based in Nidau, established in 2013. It specializes in developing and selling calcification blood test kits aimed at patients with chronic kidney diseases. The company's primary focus is on improving cardiovascular risk management for kidney patients through its calcification propensity diagnostics. Calciscon's testing services measure various indicators such as crystal formation time, serum magnesium, and fetuin-A levels, helping to identify individuals at elevated risk for pathological calcification. The company serves a diverse clientele, including researchers, clinical laboratories, and other companies, with the goal of becoming a leader in assessing, preventing, and treating biomineralization-related medical issues.

Calciscon AG is a Swiss diagnostic company based in Nidau, established in 2013. It specializes in developing and selling calcification blood test kits aimed at patients with chronic kidney diseases. The company's primary focus is on improving cardiovascular risk management for kidney patients through its calcification propensity diagnostics. Calciscon's testing services measure various indicators such as crystal formation time, serum magnesium, and fetuin-A levels, helping to identify individuals at elevated risk for pathological calcification. The company serves a diverse clientele, including researchers, clinical laboratories, and other companies, with the goal of becoming a leader in assessing, preventing, and treating biomineralization-related medical issues.

Mabimmune AG is a healthcare company based in Schlieren, Switzerland, focused on developing immunotherapeutics for solid tumors. Founded in 2013, the company employs Reverse Translational Medicine to enhance the immune system's response against tumors. By targeting and modifying the cellular infiltrate within the tumor microenvironment, Mabimmune aims to improve patient outcomes, particularly in conjunction with checkpoint inhibitors. In addition to its oncology focus, the company also specializes in early diagnosis and targeted treatment to prevent heart attacks.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular, cartridge-based system maintains sample quality, integrates with standard lab processes, and aims to make blood collection more accessible and convenient for patients and healthcare professionals.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular, cartridge-based system maintains sample quality, integrates with standard lab processes, and aims to make blood collection more accessible and convenient for patients and healthcare professionals.

Mabimmune AG is a healthcare company based in Schlieren, Switzerland, focused on developing immunotherapeutics for solid tumors. Founded in 2013, the company employs Reverse Translational Medicine to enhance the immune system's response against tumors. By targeting and modifying the cellular infiltrate within the tumor microenvironment, Mabimmune aims to improve patient outcomes, particularly in conjunction with checkpoint inhibitors. In addition to its oncology focus, the company also specializes in early diagnosis and targeted treatment to prevent heart attacks.

Mabimmune AG is a healthcare company based in Schlieren, Switzerland, focused on developing immunotherapeutics for solid tumors. Founded in 2013, the company employs Reverse Translational Medicine to enhance the immune system's response against tumors. By targeting and modifying the cellular infiltrate within the tumor microenvironment, Mabimmune aims to improve patient outcomes, particularly in conjunction with checkpoint inhibitors. In addition to its oncology focus, the company also specializes in early diagnosis and targeted treatment to prevent heart attacks.

Davos Diagnostics develops and produces systems for rapid testing. The small EVA-Systems are suited for a large variety of different analytical fields: Research IVD & Medical diagnostics Food quality control Environmental analysis Forensics Veterinary Quality control Davos Diagnostics EVA-System, is a unique rapid test system for quantitative tests, and will allow identifying multiple parameters in parallel with just a few drops of serum or plasma the patient. The sample is placed in the disposable EVA-Chip and measured in the small EVA-Reader instrument. The easy-to-use test kits (instrument, consumables, reagents) by Davos Diagnostics exploit the unique advantaged of the proprietary EVA-Biosensor Technology and will enable rapid, sensitive diagnostic tests. The small advanced optical EVA-Reader instrument, can be placed directly in every lab for decentralized quantitative biochemical testing at any place where needed by any person. This offers optimal, cost-effective workflow in research, quality control and analytical laboratories and – most important – with a few manipulation steps the results are available within 10 minutes.

KB Medical SA is a Swiss company that specializes in the design, development, and marketing of robotic assistance systems for the healthcare industry, particularly in spinal surgery. Founded in 2012 and based in Ecublens, Switzerland, the company offers the AQrate robotic system, which assists surgeons during spinal fusion procedures. This technology enhances surgical precision, reduces the risk of complications, and minimizes radiation exposure for the operating room team. By providing a less hazardous work environment, KB Medical aims to improve patient outcomes and quality of life post-surgery while also lowering overall treatment costs. The company’s operations comply with ISO 13485 standards, ensuring quality in the design and manufacture of its robotic systems. In 2017, KB Medical became a subsidiary of Globus Medical, Inc.

SpiroChem AG is a Swiss fine chemicals company based in Basel, specializing in the design, synthesis, production, and commercialization of novel building blocks for drug discovery. Founded in 2011, SpiroChem provides a diverse range of chemical entities, including bicyclo[1.1.1]pentanes, cubanes, oxetanes, spirocycles, and various other molecular fragments, tailored to support pharmaceutical, agrochemical, and life science sectors. The company leverages advanced drug design expertise and proprietary process chemistry technologies to enhance the capabilities of its clients in accelerating drug discovery and optimizing lead compounds. SpiroChem's extensive portfolio and associated services enable medicinal chemists to improve the absorption, distribution, metabolism, and excretion (ADME) properties of compounds, thereby facilitating the development of more effective drugs. Its global client base includes many leading pharmaceutical companies, reflecting SpiroChem's reputation as a preferred partner in the industry.

BioScript revolutionized the prescription process, enabling healthcare providers to streamline service delivery. The platform has significantly reduced prescription errors, increased patient safety, and improved the overall healthcare experience. It develops cutting-edge biometric technology to enhance safety and convenience in healthcare operations, quickly establishing our presence in the industry.

Calosens is developing an analytical device for the in-vitro-diagnostics market that allows to analyse probes much faster, more sensitive (+/- 3nW) and more specific. In cases of bacterial infections (Meningitis/Sepsis) there is still a high mortality rate of up to 30% as the adequate medication and dose can not be appointed fast enough. This will improve with our device resulting in higher survival rates and reducing the risks of building new antibiotic resistance.

Malcisbo AG is a biopharmaceutical company based in Zurich, Switzerland, founded in 2010. It specializes in the development of carbohydrate-based vaccines aimed at improving human and animal health. The company focuses on creating vaccines for parasitic, bacterial, and zoonotic diseases, as well as addressing human food safety concerns. Notable products include a campylobacter vaccine for broiler chickens to reduce the risk of human food poisoning, a haemonchus vaccine for small ruminants to mitigate economic losses in food production, and vaccines targeting heartworm and hookworm infections in dogs and humans. Malcisbo leverages its proprietary target discovery platform to identify carbohydrates as vaccine targets and utilizes glycoengineering technologies to develop efficient glycoconjugate vaccines. The company's goal is to create affordable vaccines that protect vulnerable populations in underdeveloped regions from parasitic infections.

BioScript revolutionized the prescription process, enabling healthcare providers to streamline service delivery. The platform has significantly reduced prescription errors, increased patient safety, and improved the overall healthcare experience. It develops cutting-edge biometric technology to enhance safety and convenience in healthcare operations, quickly establishing our presence in the industry.

BARD1 Life Sciences Limited is an Australian company dedicated to the research and development of non-invasive diagnostic tests aimed at the early detection of cancer. Its product offerings include the hTERT test for bladder cancer diagnosis and the development-stage BARD1 autoantibody tests targeting ovarian, breast, and lung cancers. The company also features the hTERT ICC test, which utilizes immunocytochemistry to detect a component of telomerase, and the EXO-NET technology for capturing and isolating exosomes from liquid biopsy samples. Additionally, BARD1 is exploring further diagnostic projects for prostate, breast, and other cancers, alongside a research-stage cancer vaccine. Established in 1983 and headquartered in South Perth, BARD1 Life Sciences is focused on advancing early cancer detection and prevention to enhance patient outcomes.

YouRehab Ltd. specializes in developing innovative rehabilitation devices aimed at enhancing patient independence during recovery. Founded in 2010 and based in Zurich, Switzerland, the company offers products like YouGrabber, which focuses on upper limb rehabilitation, and YouKicker, designed for lower limb therapy. These devices utilize advanced sensor technology and gamification techniques to motivate patients, enabling them to engage in more intensive and successful rehabilitation. YouRehab acts as a connector between electronic portable devices and interactive training games available on smartphones, facilitating data exchange with a web platform. By collaborating with a network of academic, technology, and clinical partners, the company remains at the forefront of rehabilitation technology development. As of November 2017, YouRehab operates as a subsidiary of Reha-Stim Medtec GmbH & Co. KG.